Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Symptomatic hypercalcaemia in lung cancer.

J H Campbell1, S Ralston, I T Boyle

  • 1Department for Respiratory Medicine, Glasgow Royal Infirmary, U.K.

Respiratory Medicine
|May 1, 1991
PubMed
Summary

Treating hypercalcaemia in advanced lung cancer significantly improves symptoms, even with a poor prognosis. This management is worthwhile for enhancing patient well-being.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pain after osteoporotic fractures using mouse models and patient samples.

Journal of bone and mineral metabolism·2025
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Lawson Criterion for Ignition Exceeded in an Inertial Fusion Experiment.

Physical review letters·2022
Same author

The relationship between obesity and fractures.

Injury·2019
Same author

A snapshot of biologic drug development: Challenges and opportunities.

Human & experimental toxicology·2015
Same author

Management of glucocorticoid-induced osteoporosis.

Calcified tissue international·2012

Area of Science:

  • Oncology
  • Endocrinology
  • Nephrology

Background:

  • Symptomatic hypercalcaemia is a serious complication in advanced lung cancer.
  • It often leads to rapid clinical deterioration and requires urgent management.

Purpose of the Study:

  • To evaluate the presentation and management of symptomatic hypercalcaemia in advanced lung cancer patients.
  • To assess the effectiveness of different treatment strategies on symptom reduction and biochemical response.

Main Methods:

  • Retrospective analysis of 55 advanced lung cancer patients with hypercalcaemia (serum calcium > 2.75 mmol/l) admitted between 1981-1987.
  • Patients received rehydration and varied treatments including steroids, calcitonin, mithramycin, and aminohydroxypropylidene bisphosphonate (APD).
  • Symptom categorization and biochemical monitoring were performed pre- and post-treatment.

Main Results:

  • A significant reduction in hypercalcaemia-related symptoms was observed, particularly for central nervous system and renal tract issues (75% and 80% reduction, respectively).
  • Overall, 82% of patients showed a biochemical response, with serum calcium levels decreasing significantly (P < 0.001).
  • Despite a median survival of 42 days, 49% of patients were discharged home.

Conclusions:

  • Treatment of hypercalcaemia in advanced lung cancer provides significant symptomatic improvement and is clinically worthwhile.
  • Effective management can enhance the quality of life for these patients, despite their poor prognosis.
  • Aminohydroxypropylidene bisphosphonate (APD) emerged as a key treatment in later years of the study.

Related Experiment Videos